News

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...
Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...
Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...
"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Now, a new evidence review has identified the most effective treatments for people who suffer from chronic hives.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, ...
The European Medicines Agency's Committee for Medicinal Products for Human Use has backed the use of a new type of a ...
Skyrizi came out with the largest Q2 impressions share of voice (SOV) spot for over-the-counter (OTC) pharma and Rx brands for the second year in a row, according to iSpot.tv data released this week.
The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.
Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...